Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BILZ | -19.95% | $871.57M | 0.14% |
VIXY | -19.17% | $126.83M | 0.85% |
TAIL | -18.99% | $118.71M | 0.59% |
CLIP | -16.35% | $1.51B | 0.07% |
SHYM | -14.79% | $323.08M | 0.35% |
FXC | -13.35% | $87.64M | 0.4% |
TPMN | -11.48% | $30.83M | 0.65% |
FTSD | -11.01% | $212.66M | 0.25% |
FXE | -10.58% | $520.10M | 0.4% |
IBND | -9.34% | $284.04M | 0.5% |
FXY | -8.63% | $857.57M | 0.4% |
IVOL | -8.28% | $355.73M | 1.02% |
UDN | -8.02% | $138.93M | 0.78% |
IGOV | -7.89% | $982.87M | 0.35% |
BWX | -7.23% | $1.43B | 0.35% |
GLDM | -6.94% | $14.48B | 0.1% |
URNJ | -6.82% | $229.44M | 0.8% |
BOXX | -6.47% | $6.29B | 0.19% |
IAU | -6.43% | $45.61B | 0.25% |
SGOL | -6.40% | $5.02B | 0.17% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
PPH | 60.66% | $604.48M | 0.36% |
IHE | 54.43% | $563.21M | 0.39% |
IYH | 53.56% | $2.81B | 0.39% |
XLV | 53.39% | $35.08B | 0.09% |
FHLC | 52.02% | $2.46B | 0.084% |
IXJ | 51.97% | $3.87B | 0.41% |
VHT | 51.45% | $15.32B | 0.09% |
BBH | 48.54% | $340.78M | 0.35% |
RSPH | 45.08% | $768.87M | 0.4% |
IBB | 43.38% | $5.41B | 0.45% |
FXH | 43.24% | $927.09M | 0.62% |
FBT | 43.21% | $1.05B | 0.56% |
IYK | 41.98% | $1.53B | 0.4% |
XLP | 41.68% | $16.61B | 0.09% |
XPH | 41.50% | $141.28M | 0.35% |
HDV | 40.28% | $11.08B | 0.08% |
SPHD | 39.34% | $3.25B | 0.3% |
VDC | 38.98% | $7.64B | 0.09% |
FTXG | 38.89% | $35.57M | 0.6% |
FSTA | 38.29% | $1.38B | 0.084% |
Current Value
$76.721 Year Return
Current Value
$76.721 Year Return
SeekingAlpha
Bicara: Stock Decline On FICERA Abstract Release Creates Buying Opportunity
Finnhub
Merck & Co Inc: * MERCK STATEMENT ON A POTENTIAL REDUCED DOSINGRECOMMENDATION FORGARDASIL®9 * AFFIRMED POSITION REGARDING ALTERNATE DOSING REGIMENS FORGARDASIL®9 FOR...
SeekingAlpha
Merck: Dividend Near A 12-Year High, But I Won't Buy - Here's Why
SeekingAlpha
Merck is expanding in oncology, immunology, and vaccines through acquisitions and R&D. Find out what makes MRK a stable GARP buy in a volatile macro environment.
DowJones
Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics
Finnhub
May 23, 2025 8:00 am ET RAHWAY, N.J., May 23, 2025 - Merck , known as MSD outside of the United States and Canada, today affirmed its position regarding alternate dosing regimens for...
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTF | 0.03% | $34.07M | 1.25% |
CRPT | -0.04% | $115.57M | 0.85% |
BITB | 0.04% | $4.09B | 0.2% |
BRRR | 0.08% | $647.70M | 0.25% |
SATO | 0.11% | $10.84M | 0.6% |
IAGG | -0.12% | $7.34B | 0.07% |
SPTS | 0.14% | $5.74B | 0.03% |
FBTC | 0.15% | $21.33B | 0.25% |
HODL | 0.15% | $1.58B | 0.25% |
BITO | -0.18% | $2.54B | 0.95% |
IBIT | 0.19% | $67.90B | 0.25% |
ARKB | 0.21% | $5.23B | 0.21% |
BKCH | -0.24% | $162.06M | 0.5% |
UTWO | 0.30% | $384.90M | 0.15% |
CONY | -0.31% | $1.17B | 1.22% |
TESL | -0.32% | $31.34M | 1.2% |
EZBC | 0.33% | $541.76M | 0.29% |
JMST | 0.36% | $3.71B | 0.18% |
SMB | -0.41% | $269.48M | 0.07% |
IZRL | 0.44% | $104.40M | 0.49% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
MGNI | -0.01% | $2.20B | +40.92% | 0.00% |
CHEF | -0.01% | $2.51B | +60.57% | 0.00% |
VRT | 0.02% | $39.71B | +2.92% | 0.12% |
WHWK | 0.02% | $88.57M | +3.30% | 0.00% |
PGC | -0.03% | $480.29M | +20.36% | 0.74% |
LAW | -0.04% | $238.97M | -35.89% | 0.00% |
DCTH | -0.04% | $562.44M | +105.73% | 0.00% |
FUTU | -0.04% | $10.56B | +54.56% | 0.00% |
MARA | -0.04% | $5.51B | -22.06% | 0.00% |
MTLS | -0.05% | $301.83M | -0.58% | 0.00% |
SBSI | 0.05% | $849.62M | +5.67% | 6.51% |
EDN | 0.05% | $794.21M | +122.69% | 0.00% |
QTTB | -0.05% | $20.13M | -94.39% | 0.00% |
API | -0.05% | $273.38M | +45.45% | 0.00% |
TBI | -0.05% | $169.03M | -47.59% | 0.00% |
LYFT | -0.06% | $6.73B | +3.63% | 0.00% |
JBL | 0.07% | $17.72B | +38.98% | 0.20% |
HAFC | 0.08% | $690.35M | +46.10% | 4.57% |
UIS | 0.09% | $346.10M | +7.98% | 0.00% |
DNOW | -0.09% | $1.54B | +3.55% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
IMNN | -24.59% | $7.29M | -71.34% | 0.00% |
SFM | -16.66% | $15.83B | +100.48% | 0.00% |
CVLT | -16.31% | $7.74B | +58.55% | 0.00% |
PLOW | -15.08% | $630.37M | +7.22% | 4.41% |
QNTM | -12.49% | $28.10M | -47.59% | 0.00% |
ORN | -11.92% | $316.83M | -4.42% | 0.00% |
VRNS | -11.62% | $5.23B | +4.96% | 0.00% |
LMB | -11.22% | $1.46B | +124.72% | 0.00% |
PLTR | -11.21% | $288.59B | +490.20% | 0.00% |
OKLO | -10.95% | $5.53B | +423.32% | 0.00% |
NGVC | -10.88% | $1.15B | +140.90% | 0.88% |
RLGT | -10.85% | $287.57M | +18.45% | 0.00% |
OR | -10.79% | $4.66B | +54.51% | 0.73% |
CNTY | -10.54% | $61.06M | -24.05% | 0.00% |
UEC | -10.23% | $2.21B | -26.70% | 0.00% |
IIIV | -10.19% | $612.54M | +32.70% | 0.00% |
CNK | -10.10% | $3.73B | +82.76% | 0.25% |
FMTO | -9.96% | $42.10M | -99.95% | 0.00% |
NCMI | -9.79% | $465.86M | -3.52% | 0.61% |
IESC | -9.73% | $4.80B | +52.44% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
PFE | 45.98% | $130.99B | -19.69% | 7.41% |
PG | 43.72% | $386.92B | -0.28% | 2.47% |
ECL | 43.00% | $73.62B | +11.38% | 0.95% |
CLX | 42.04% | $16.13B | -0.30% | 3.72% |
AMGN | 41.86% | $146.20B | -11.29% | 3.43% |
ABBV | 41.34% | $322.44B | +15.34% | 3.50% |
ZTS | 40.74% | $72.11B | -5.23% | 1.16% |
BIIB | 40.62% | $18.51B | -42.08% | 0.00% |
AZN | 40.40% | $216.93B | -10.53% | 2.21% |
PEP | 39.19% | $178.40B | -27.42% | 4.19% |
REGN | 38.21% | $64.44B | -39.13% | 0.15% |
NVS | 37.76% | $213.48B | +11.27% | 3.56% |
TMO | 37.66% | $151.18B | -31.55% | 0.40% |
EL | 37.62% | $23.18B | -48.93% | 3.18% |
GIS | 37.34% | $29.20B | -22.80% | 4.50% |
GILD | 37.25% | $132.78B | +61.31% | 2.94% |
ENR | 36.90% | $1.65B | -21.26% | 5.26% |
JNJ | 36.60% | $367.19B | +1.94% | 2.43% |
KMB | 35.70% | $46.37B | +6.00% | 3.51% |
BMY | 35.40% | $95.71B | +13.22% | 5.21% |
Double maintains 16 strategies that include MRK - Merck & Co., Inc.